Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
16.81
+0.47 (+2.88%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
7,446,849
Open
16.31
Bid (Size)
16.12 (2)
Ask (Size)
17.03 (1)
Prev. Close
16.34
Today's Range
16.31 - 16.88
52wk Range
8.055 - 17.69
Shares Outstanding
1,110,352,397
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
July 19, 2024
Via
Benzinga
Teva's Migraine Treatment Found Effective For Children As Young As 6
July 18, 2024
Teva Pharmaceutical's Phase 3 SPACE study reveals Ajovy's significant efficacy in preventing episodic migraines in children aged 6-17. The trial's primary endpoint was met with safety data aligning...
Via
Benzinga
Performance
YTD
+57.54%
+57.54%
1 Month
-1.47%
-1.47%
3 Month
+30.51%
+30.51%
6 Month
+46.30%
+46.30%
1 Year
+97.53%
+97.53%
More News
Read More
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
July 18, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
July 17, 2024
Via
Benzinga
Breaking Down Teva Pharmaceutical Indus: 5 Analysts Share Their Views
June 27, 2024
Via
Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today
June 12, 2024
Via
Benzinga
4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
May 30, 2024
Via
Benzinga
3 No-Brainer Stocks to Buy With $200 Right Now
July 17, 2024
Via
The Motley Fool
Here's How Much $1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
July 16, 2024
Via
Benzinga
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
July 10, 2024
Via
MarketBeat
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
July 02, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
FTC Crackdown on Teva Pharmaceuticals Over Inhaler Patent Abuse
July 01, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Dr. Reddy's Labs Stock Sees Improved Technical Strength
June 28, 2024
Via
Investor's Business Daily
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
June 28, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
June 25, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
June 24, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Engages In Settlement Talks Over Medicare Kickback Allegations
June 18, 2024
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know
June 14, 2024
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
7 A-Rated Biotech Stocks Worth Betting on in June
June 14, 2024
Via
InvestorPlace
What is a Bull Flag Pattern? Explanation and Examples
June 13, 2024
Via
MarketBeat
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
June 01, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
June 01, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
2 Generic Drug Makers With Growing Runways
May 31, 2024
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
May 29, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.